Life is busy enough

RAVICTI® (glycerol phenylbutyrate) Oral Liquid offers 24/7 ammonia control with easy dosing for busy lives.1,a

Explore RAVICTI

RAVICTI is indicated for the chronic management of patients with UCDs ≥2 months of age who cannot be managed by diet and supplementation alone. It must be used with dietary protein restriction.1

RAVICTI is not indicated for the treatment of acute hyperammonemia or for NAGS deficiency, and is contraindicated in patients <2 months of age.1

RAVICTI HCP

Important information

  • Of the 17 pediatric patients 2 months to <2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises.1
  • Of the 26 pediatric patients 6 to 17 years of age in two 12-month studies of RAVICTI, 5 patients (19%) reported a total of 5 hyperammonemic crises.1
  • Of 51 adult patients in a 12-month study of RAVICTI, 7 patients (14%) reported a total of 10 hyperammonemic crises.1

aSix uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonemic crises in patients with urea cycle disorders (UCDs): 17 pediatric patients 2 months to <2 years of age, with 6 patients completing 12 months of treatment; 26 pediatric patients 6 to 17 years of age over a 12-month period; and 51 adults over a 12-month period.1

Get information about RAVICTI dosing

How to calculate the appropriate starting dose for treatment-naïve patients, convert the dosage from NaPBA to RAVICTI, and optimize the RAVICTI dosage

Visit Dosage Guide

References:  1. RAVICTI [package insert]. Lake Forest, IL: Horizon Pharma USA, Inc.; 2017.  2. Mosteller RD. N Engl J Med. 1987;317(17):1098. doi:10.1056/nejm198710223171717.

Meta Keywords
RAVICTI, urea cycle disorder, hyperammonemia, RAVICTI dosing, RAVICTI dose, RAVICTI prescribing information, glycerol phenylbutyrate, UCD treatment, urea cycle disorder treatment, urea cycle defect, nitrogen scavenger, ammonia control, RAVICTI efficacy, RAVICTI safety